Curaleaf continues to expand access to innovative medical cannabis solutions worldwide with the international rollout of the Que Medical Inhalation Device (QMID).
Developed to meet EU medical-device standards, QMID is the world’s first CE-certified medical cannabis liquid inhaler delivering precision, consistency, and discretion for patients.
We are proud to announce that QMID is now accessible for patients in the UK, Australia, Poland, Switzerland, Canada and Germany, with a prescription.
Poland: First Registered Medical Inhalation Device
Through close collaboration between Curaleaf’s International Product Team and the local Polish team, Curaleaf Poland has introduced the first registered medical cannabis inhalation device to the Polish market. The device is available immediately through pharmacies.
Canada: Expanding Access Through My Medi
Canada has also launched QMID, further strengthening Curaleaf’s global footprint.
Patients in Canada can now access the CE-certified medical cannabis liquid inhaler via prescription through the My Medi medical platform.
We extend our thanks to the Canadian team and the International Product Team whose collaboration made this launch possible.
Switzerland: Partnership with Dascoli Pharma
In Switzerland, QMID has launched through a partnership with Dascoli Pharma.
The CE-certified medical cannabis liquid inhaler is now available to patients via prescription, expanding access to regulated, device-led treatment options in the Swiss market.
Commenting on the launch, Juan Pablo Martínez Pavón, CEO of Curaleaf International, said:
“Across Poland, Canada, and Switzerland, the QMID launch reflects Curaleaf’s broader commitment: shaping the global future of medical cannabis through innovation, regulatory alignment, and patient-centric design.
By focusing on clinically validated, standardised delivery systems, Curaleaf continues to expand access to safe, precise, and medically integrated cannabis treatments worldwide.
We thank every team and partner involved in bringing QMID to new markets and look forward to continuing this important work together.”
